As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

One of the biggest benefits of creating a single source of truth for label data is the elimination of data silos. Instead of data being scattered across the company, the most accurate and up-to-date ...

In this post, we will discuss some free spreadsheets with no login-required services that you can use - Retable, Tablesmith, ...

Meta Platforms' 49% stock surge in 2023, driven by AI advancements. Explore its growth potential, undervaluation, and EPS forecast through 2027.

Uploading files for analysis and summarization can take a basic chatbot to the next level, turning it into a much more ...